ROIV - Company ID 0001635088
The table below shows Roivant Sciences Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $2.00M | $1.57M | $2.17M | $9.02M | $4.47M | $7.99M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $165.38M | $164.57M | $152.92M | $141.59M | $143.07M | $120.51M |
Roivant Sciences Ltd. reported annual revenue of $8.26M for fiscal year 2026. That is down 71.6% from $29.05M in fiscal 2025. Over the 6 fiscal years shown, annual revenue declined from $23.80M (FY 2021) to $8.26M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $175.07M |
| $143.13M |
| $134.02M |
| $141.54M |
| $202.88M |
| $148.52M |
| Operating income | -$339.15M | -$306.23M | -$284.92M | -$274.38M | -$341.71M | -$102.23M |
| Income tax | $23.33M | $7.00M | $4.65M | -$25.57M | $12.46M | $11.96M |
| Net income | -$265.89M | -$113.52M | -$223.35M | $169.38M | -$230.18M | $95.30M |
| EPS (diluted) | -$0.38 | -$0.17 | -$0.33 | $0.23 | -$0.31 | $0.12 |